Published in PLoS One on February 19, 2015
Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin (2015) 0.88
Rhinovirus stimulated IFN-α production: how important are plasmacytoid DCs, monocytes and endosomal pH? Clin Transl Immunology (2015) 0.76
U1-RNP and Toll-like receptors in the pathogenesis of mixed connective tissue diseasePart II. Endosomal TLRs and their biological significance in the pathogenesis of mixed connective tissue disease. Reumatologia (2015) 0.75
Synthetic Human TLR9-LRR11 Peptide Attenuates TLR9 Signaling by Binding to and thus Decreasing Internalization of CpG Oligodeoxynucleotides. Int J Mol Sci (2016) 0.75
Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics. Front Physiol (2017) 0.75
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 11.05
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol (2006) 6.00
Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (2006) 5.30
UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature (2008) 5.15
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods (1993) 4.11
Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol (2007) 4.09
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature (2008) 3.93
Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest (2005) 3.93
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol (2007) 3.72
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A (2006) 3.70
Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol (2001) 3.64
Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol (2008) 3.61
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med (2007) 3.45
Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat Immunol (2004) 3.18
Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med (2005) 2.89
Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol (2000) 2.59
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature (2010) 2.31
Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol (2002) 1.80
Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev (2011) 1.78
Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol (2008) 1.78
U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood (2005) 1.74
Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity (2011) 1.59
Competition by inhibitory oligonucleotides prevents binding of CpG to C-terminal TLR9. Eur J Immunol (2011) 1.52
TLR8 deficiency leads to autoimmunity in mice. J Clin Invest (2010) 1.46
Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol (2005) 1.36
Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis (2014) 1.11
Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun (2009) 1.07
DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo. Arthritis Res Ther (2009) 1.07
Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm (2010) 1.01
Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology (2007) 0.98
Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol (2006) 0.95
Role of nucleic acid-sensing TLRs in diverse autoantibody specificities and anti-nuclear antibody-producing B cells. J Immunol (2013) 0.95
Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. Int Immunol (2011) 0.94
TLRs and interferons: a central paradigm in autoimmunity. Curr Opin Immunol (2013) 0.85
Love triangle between Unc93B1, TLR7, and TLR9 prevents fatal attraction. Immunity (2011) 0.82
Guanine modification of inhibitory oligonucleotides potentiates their suppressive function. J Immunol (2013) 0.77
Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9. Int Immunopharmacol (2011) 0.76